Improve Research Reproducibility A Bio-protocol resource
- Home
- Protocols
-
Ask a
question
Favorite
Viloxazine was assessed by using the Cerep BioprintTM panel (Eurofins, France) equipped with 132 cell-based proprietary assays, including a variety of receptors (82 assays), ion channels (14 assays), monoamine oxidase-A (MAO-A), and neurotransmitter transporters such as the NE, DA, 5-HT, gamma-aminobutyric acid (GABA), and ACh transporters. Binding affinity of viloxazine (10 µM) was represented as a percent inhibition of the binding of a radiolabeled ligand specific for each target. Inhibition higher than 50% was considered significant.
Copyright and License information: ©2020 Yu et al.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Post a Question0 Q&A
